Helena Taflin1, Elisabeth Odin1, Göran Carlsson1, Roger Tell2, Bengt Gustavsson1, Yvonne Wettergren3. 1. Department of Surgery, The Institute of Clinical Sciences, The Sahlgrenska Academy At University of Gothenburg, Göteborg, Sweden. 2. Isofol Medical AB, Göteborg, Sweden. 3. Department of Surgery, The Institute of Clinical Sciences, The Sahlgrenska Academy At University of Gothenburg, Göteborg, Sweden. yvonne.wettergren@gu.se.
Abstract
PURPOSE: The aim was to explore the correlation between increasing doses of [6R]-5,10-methylenetetrahydrofolate (arfolitixorin) and plasma concentrations of deoxyuridine (dUr) in patients with metastatic colorectal cancer (mCRC), subjected to 5-fluorouracil (5-FU)-based chemotherapy. The aim was further to investigate the possibility to predict toxicity and clinical response during treatment using gender, age, and plasma dUr as explanatory variables. METHODS: Thirty-three patients from the ISO-CC-005 phase I/IIa study, which investigated safety and tolerability of arfolitixorin at four dose levels, were included. Toxicity and clinical response were evaluated after 4 cycles of chemotherapy. Plasma dUr was quantified before (0 h) and 24 h after 5-FU administration at the first (C1) and fourth (C4) cycle using LC-MS/MS. Fit modelling was used to predict toxicity and clinical response. RESULTS: The dUr levels increased with increasing arfolitixorin dose. Females had higher total and haematological toxicity scores (p = 0.0004 and 0.0089, respectively), and needed dose reduction more often than males (p = 0.012). Fit modeling showed that gender and the dUr levels at C1-0 h and C4-24 h predicted total toxicity (p = 0.0011), whereas dUr C4-0 h alone was associated with gastrointestinal toxicity (p = 0.026). Haematological toxicity was predicted by gender and age (p = 0.0071). The haematological toxicity score in combination with the dUr levels at C1-24 h and C4-24 h predicted early clinical response (p = 0.018). CONCLUSION: The dUr level before and during administration of 5-FU and arfolitixorin was predictive for toxicity and early clinical response and could be a potential surrogate marker for thymidylate synthase inhibition in patients with mCRC. TRIAL REGISTRATION: NCT02244632, first posted on ClinicalTrials.gov on September 19, 2014.
PURPOSE: The aim was to explore the correlation between increasing doses of [6R]-5,10-methylenetetrahydrofolate (arfolitixorin) and plasma concentrations of deoxyuridine (dUr) in patients with metastatic colorectal cancer (mCRC), subjected to 5-fluorouracil (5-FU)-based chemotherapy. The aim was further to investigate the possibility to predict toxicity and clinical response during treatment using gender, age, and plasma dUr as explanatory variables. METHODS: Thirty-three patients from the ISO-CC-005 phase I/IIa study, which investigated safety and tolerability of arfolitixorin at four dose levels, were included. Toxicity and clinical response were evaluated after 4 cycles of chemotherapy. Plasma dUr was quantified before (0 h) and 24 h after 5-FU administration at the first (C1) and fourth (C4) cycle using LC-MS/MS. Fit modelling was used to predict toxicity and clinical response. RESULTS: The dUr levels increased with increasing arfolitixorin dose. Females had higher total and haematological toxicity scores (p = 0.0004 and 0.0089, respectively), and needed dose reduction more often than males (p = 0.012). Fit modeling showed that gender and the dUr levels at C1-0 h and C4-24 h predicted total toxicity (p = 0.0011), whereas dUrC4-0 h alone was associated with gastrointestinal toxicity (p = 0.026). Haematological toxicity was predicted by gender and age (p = 0.0071). The haematological toxicity score in combination with the dUr levels at C1-24 h and C4-24 h predicted early clinical response (p = 0.018). CONCLUSION: The dUr level before and during administration of 5-FU and arfolitixorin was predictive for toxicity and early clinical response and could be a potential surrogate marker for thymidylate synthase inhibition in patients with mCRC. TRIAL REGISTRATION: NCT02244632, first posted on ClinicalTrials.gov on September 19, 2014.
Authors: C E de Bock; M B Garg; N Scott; J A Sakoff; F E Scorgie; S P Ackland; L F Lincz Journal: Pharmacogenomics J Date: 2010-06-08 Impact factor: 3.550
Authors: Hugo E R Ford; Fraser Mitchell; David Cunningham; David C Farrugia; Mark E Hill; Charlotte Rees; A Hilary Calvert; Ian R Judson; Ann L Jackman Journal: Clin Cancer Res Date: 2002-01 Impact factor: 12.531
Authors: Peter V Danenberg; Bengt Gustavsson; Patrick Johnston; Per Lindberg; Rudolf Moser; Elisabeth Odin; Godefridus J Peters; Nicholas Petrelli Journal: Crit Rev Oncol Hematol Date: 2016-08-09 Impact factor: 6.312
Authors: Paulo M Hoff; Everardo D Saad; Frederico Costa; Anelisa K Coutinho; Ricardo Caponero; Gabriel Prolla; Rene C Gansl Journal: Clin Colorectal Cancer Date: 2011-12-06 Impact factor: 4.481
Authors: R M Mader; G G Steger; B Rizovski; M P Djavanmard; W Scheithauer; R Jakesz; H Rainer Journal: Br J Clin Pharmacol Date: 1995-09 Impact factor: 4.335
Authors: P Thirion; S Michiels; J P Pignon; M Buyse; A C Braud; R W Carlson; M O'Connell; P Sargent; P Piedbois Journal: J Clin Oncol Date: 2004-09-15 Impact factor: 44.544